These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 27126611)

  • 1. N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.
    Jennings GK; Ritchie CM; Shock LS; Lyons CE; Hackett JC
    Mol Pharmacol; 2016 Jul; 90(1):42-51. PubMed ID: 27126611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process.
    Guengerich FP; McCarty KD; Chapman JG
    J Biol Chem; 2021; 296():100223. PubMed ID: 33449875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism.
    Sevrioukova IF; Poulos TL
    Curr Top Med Chem; 2014; 14(11):1348-55. PubMed ID: 24805065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pyridine-substituted desoxyritonavir is a more potent inhibitor of cytochrome P450 3A4 than ritonavir.
    Sevrioukova IF; Poulos TL
    J Med Chem; 2013 May; 56(9):3733-41. PubMed ID: 23586711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of CYP3A4 with the inhibitor cobicistat: Structural and mechanistic insights and comparison with ritonavir.
    Sevrioukova IF
    Arch Biochem Biophys; 2024 Aug; 758():110071. PubMed ID: 38909836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An increase in side-group hydrophobicity largely improves the potency of ritonavir-like inhibitors of CYP3A4.
    Samuels ER; Sevrioukova IF
    Bioorg Med Chem; 2020 Mar; 28(6):115349. PubMed ID: 32044230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-Activity Relationships of Rationally Designed Ritonavir Analogues: Impact of Side-Group Stereochemistry, Headgroup Spacing, and Backbone Composition on the Interaction with CYP3A4.
    Samuels ER; Sevrioukova I
    Biochemistry; 2019 Apr; 58(15):2077-2087. PubMed ID: 30912932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4.
    Rock BM; Hengel SM; Rock DA; Wienkers LC; Kunze KL
    Mol Pharmacol; 2014 Dec; 86(6):665-74. PubMed ID: 25274602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues.
    Sevrioukova IF; Poulos TL
    Biochemistry; 2013 Jul; 52(26):4474-81. PubMed ID: 23746300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir.
    Sevrioukova IF; Poulos TL
    Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18422-7. PubMed ID: 20937904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.
    Kaur P; Chamberlin AR; Poulos TL; Sevrioukova IF
    J Med Chem; 2016 May; 59(9):4210-20. PubMed ID: 26371436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding free energies of inhibitors to iron porphyrin complex as a model for Cytochrome P450.
    Lee JY; Kang NS; Kang YK
    Biopolymers; 2012 Apr; 97(4):219-28. PubMed ID: 22113809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The X-Ray Crystal Structure of the Human Mono-Oxygenase Cytochrome P450 3A5-Ritonavir Complex Reveals Active Site Differences between P450s 3A4 and 3A5.
    Hsu MH; Savas U; Johnson EF
    Mol Pharmacol; 2018 Jan; 93(1):14-24. PubMed ID: 29093019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic Studies of Cytochrome P450 3A4 Time-Dependent Inhibition Using Two Cysteine-Targeting Electrophiles.
    Barr JT; Wang Z; Min X; Wienkers HJ; Rock BM; Rock DA; Wienkers LC
    Drug Metab Dispos; 2020 Jun; 48(6):508-514. PubMed ID: 32193357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of CYP3A4 with Rationally Designed Ritonavir Analogues: Impact of Steric Constraints Imposed on the Heme-Ligating Group and the End-Pyridine Attachment.
    Samuels ER; Sevrioukova IF
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of Human Drug-Metabolizing CYP3A4 with Small Inhibitory Molecules.
    Sevrioukova I
    Biochemistry; 2019 Feb; 58(7):930-939. PubMed ID: 30676743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
    Loos NHC; Beijnen JH; Schinkel AH
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
    Nembri S; Grisoni F; Consonni V; Todeschini R
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety.
    Mandal M; Mitra K; Grotz D; Lin X; Palamanda J; Kumari P; Buevich A; Caldwell JP; Chen X; Cox K; Favreau L; Hyde L; Kennedy ME; Kuvelkar R; Liu X; Mazzola RD; Parker E; Rindgen D; Sherer E; Wang H; Zhu Z; Stamford AW; Cumming JN
    J Med Chem; 2018 Dec; 61(23):10700-10708. PubMed ID: 30388368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clobetasol Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5.
    Wright WC; Chenge J; Wang J; Girvan HM; Yang L; Chai SC; Huber AD; Wu J; Oladimeji PO; Munro AW; Chen T
    J Med Chem; 2020 Feb; 63(3):1415-1433. PubMed ID: 31965799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.